Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 16;14(6):2018.
doi: 10.3390/jcm14062018.

Predicting New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Review

Affiliations
Review

Predicting New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Review

Marco Maria Dicorato et al. J Clin Med. .

Abstract

Hypertrophic cardiomyopathy (HCM) is a condition characterized by left ventricular hypertrophy, with physiopathological remodeling that predisposes patients to atrial fibrillation (AF). The electrocardiogram is a basic diagnostic tool for evaluating heart electrical activity. Key electrocardiographic features that correlate with AF onset are P-wave duration, P-wave dispersion, and electromechanical delay in left atrium (LA). Clinical markers, including age, body mass index, New York Heart Association functional class, and heart failure symptoms, are also strong predictors of AF in HCM. Risk scores have been created using multiple variables to better predict AF development. Increasing knowledge of genetic subsets in HCM and cardiovascular pathology in general has provided novel insight in this context. Structural and mechanical LA remodeling, including fibrosis, altered LA function, and changes in atrial size, further contribute to AF risk prediction. Cardiovascular magnetic resonance (CMR) and echocardiographic measures provide accurate information about atrial structure and function. Machine learning models are increasingly being utilized to refine risk prediction, incorporating a wide range of variables. This review highlights the multifaceted approach required to understand and predict AF development in HCM. Such an approach is imperative to enhance prognostic accuracy and improve the quality of life of these patients. Further research is necessary to refine patient outcomes and develop customized management strategies for HCM-associated AF.

Keywords: atrial cardiomyopathy; atrial fibrillation (AF); cardiovascular magnetic resonance (CMR); echocardiography; electrocardiogram (ECG); genetics; heart failure; hypertrophic cardiomyopathy (HCM); left atrial remodeling; machine learning.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The image shows the sinus rhythm electrocardiogram (ECG) of a 60-year-old patient affected by hypertrophic cardiomyopathy (HCM), who developed atrial fibrillation during the follow-up. P-wave electrocardiographic features are measured. Maximum P-wave duration (Pdurmax) is 150 milliseconds (ms), recorded in lead V2. P-wave dispersion (PWD) is given by the difference between Pdurmax and minimum Pdur (Pdurmin), which is calculated in lead V5 in this case. PWD is calculated as follows: PWD = Pdurmax − Pdurmin = PdurV2 − PdurV5 = 150 ms − 80 ms = 70 ms. Higher values of Pdurmax and PWD have been demonstrated to be associated with atrial fibrillation onset in HCM patients. This ECG explains how ECG data can contribute to the prediction of atrial fibrillation in HCM.
Figure 2
Figure 2
Clinical case of a patient affected by hypertrophic cardiomyopathy (HCM) who experienced a paroxysmal episode of atrial fibrillation (AF). The image shows echocardiographic measurements of various variables which have been demonstrated to be associated with AF onset in HCM. (a) Severely increased left atrial antero-posterior diameter (≥45 mm). (b) E/e’ ratio ≥ 17, suggesting elevated left ventricular filling pressures. (c) Marked dilation of left atrial area (≥28 cm2) and left atrial volume index (≥34 mL/m2). (d) Impaired left atrial ejection fraction (≤45%). (e) Alterations in the three left atrial phasic functions (reservoir, conduit, pump), assessed by strain-derived measures.

References

    1. Maron B.J., Desai M.Y., Nishimura R.A., Spirito P., Rakowski H., Towbin J.A., Dearani J.A., Rowin E.J., Maron M.S., Sherrid M.V. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2022;79:390–414. doi: 10.1016/j.jacc.2021.11.021. - DOI - PubMed
    1. Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., Barriales-Villa R., Basso C., Bezzina C.R., Biagini E., Blom N.A., de Boer R.A., et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur. Heart J. 2023;44:3503–3626. doi: 10.1093/eurheartj/ehad194. - DOI - PubMed
    1. Finocchiaro G., Sheikh N., Biagini E., Papadakis M., Maurizi N., Sinagra G., Pelliccia A., Rapezzi C., Sharma S., Olivotto I. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020;17:142–151. doi: 10.1016/j.hrthm.2019.07.019. - DOI - PubMed
    1. Ommen S.R., Ho C.Y., Asif I.M., Balaji S., Burke M.A., Day S.M., Dearani J.A., Epps K.C., Evanovich L., Ferrari V.A., et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1239–e1311. doi: 10.1161/CIR.0000000000001250. - DOI - PubMed
    1. D’Onofrio A., Marini M., Rovaris G., Zanotto G., Calvi V., Iacopino S., Biffi M., Solimene F., Della Bella P., Caravati F., et al. Prognostic significance of remotely monitored nocturnal heart rate in heart failure patients with reduced ejection fraction. Heart Rhythm. 2023;20:233–240. doi: 10.1016/j.hrthm.2022.10.018. - DOI - PubMed

LinkOut - more resources